FDA reviewers advise no go for Novartis' serelaxin

It's never a good sign for a drug heading into an advisory committee meeting when the FDA's reviewers start off the briefing documents by advising against approval, and for Novartis, there's trouble ahead for serelaxin, a recombinant form of the human relaxin-2 hormone, which the firm is seeking to market as Reasanz.